Drug Profile
Pregabalin controlled release - Mapi Pharma
Alternative Names: Pregabalin ER - Mapi Pharma; Pregabalin extended-release - Mapi PharmaLatest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Mapi Pharma
- Developer Jiangsu Nhwa Pharmaceutical; Mapi Pharma
- Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Small molecules
- Mechanism of Action CACNA2D1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuropathic pain
Most Recent Events
- 22 Feb 2022 Phase-II development is ongoing in Neuropathic pain (Mapi Pharma pipeline, February 2022)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Neuropathic-pain in Israel (PO, Controlled release)
- 27 Oct 2016 Chemical structure information added